- Home
- PHM vs ILMN Comparison
PHM vs ILMN Comparison
Compare PHM & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHM
- ILMN
- Stock Information
- Founded
- PHM 1950
- ILMN 1998
- Country
- PHM United States
- ILMN United States
- Employees
- PHM N/A
- ILMN N/A
- Industry
- PHM Homebuilding
- ILMN Medical Specialities
- Sector
- PHM Consumer Discretionary
- ILMN Health Care
- Exchange
- PHM Nasdaq
- ILMN Nasdaq
- Market Cap
- PHM 27.2B
- ILMN 22.9B
- IPO Year
- PHM N/A
- ILMN 2000
- Fundamental
- Price
- PHM $126.80
- ILMN $141.09
- Analyst Decision
- PHM Buy
- ILMN Buy
- Analyst Count
- PHM 16
- ILMN 20
- Target Price
- PHM $145.00
- ILMN $160.68
- AVG Volume (30 Days)
- PHM 1.5M
- ILMN 2.1M
- Earning Date
- PHM 01-30-2025
- ILMN 11-04-2024
- Dividend Yield
- PHM 0.63%
- ILMN N/A
- EPS Growth
- PHM 10.14
- ILMN N/A
- EPS
- PHM 13.56
- ILMN N/A
- Revenue
- PHM $17,318,808,000.00
- ILMN $4,390,000,000.00
- Revenue This Year
- PHM $11.29
- ILMN N/A
- Revenue Next Year
- PHM $4.29
- ILMN $4.28
- P/E Ratio
- PHM $9.35
- ILMN N/A
- Revenue Growth
- PHM 2.80
- ILMN N/A
- 52 Week Low
- PHM $93.99
- ILMN $97.36
- 52 Week High
- PHM $149.47
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- PHM 39.16
- ILMN 48.42
- Support Level
- PHM $133.46
- ILMN $138.88
- Resistance Level
- PHM $136.14
- ILMN $144.00
- Average True Range (ATR)
- PHM 3.27
- ILMN 4.58
- MACD
- PHM -0.24
- ILMN -0.05
- Stochastic Oscillator
- PHM 10.22
- ILMN 69.62
About PHM PulteGroup Inc.
PulteGroup Inc is a homebuilder in the United States. The company mainly builds single-family detached homes, and offers products to entry-level, move-up, and active-adult buyers. It also offers homebuyers mortgage financing, title, and insurance agency services through its financial services segment.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.